STOCK TITAN

Aptargroup (ATR) Stock News

ATR NYSE

Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.

AptarGroup, Inc. develops drug delivery and consumer-product dosing, dispensing and protection technologies for pharmaceutical, beauty, food, beverage, personal care and home care markets. News about ATR commonly covers operating results across Pharma, Beauty and Closures, demand trends in prescription drug delivery, biologics, injectables, nasal delivery, fragrance dispensing and closure applications.

Company updates also include product introductions such as inverted lidless dispensing closures using SimpliSqueeze® valve technology, Aptar Pharma delivery systems used in clinical-stage nasal therapies, Aptar Digital Health partnerships, dividend declarations, share repurchases and investor presentations.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary

AptarGroup, Inc. (NYSE: ATR) has been recognized as one of 3BL Media's 100 Best Corporate Citizens for the second consecutive year, highlighting its commitment to environmental, social, and governance (ESG) practices. This ranking evaluates the largest U.S. public companies on 155 ESG factors. CEO Stephan B. Tanda emphasized the company’s dedication to sustainable solutions and collaboration with industry partners. Similarly, VP Beth Holland noted Aptar's proactive approach to achieving circular economy goals. The recognition reflects Aptar's ongoing efforts towards transparency and sustainability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
-
News
Rhea-AI Summary

AptarGroup, Inc. (NYSE:ATR) reported a 9% increase in first-quarter sales, reaching $845 million, boosted by double-digit core growth in all segments. Adjusted earnings per share were $0.96, down from $1.05 the previous year, impacted by a higher effective tax rate. The Pharma segment experienced significant growth due to rising demand for allergy and asthma products. Despite operational challenges, including currency headwinds and supply chain issues, the company remains optimistic about future growth. A quarterly dividend of $0.38 was declared, with share repurchases continuing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
News
Rhea-AI Summary

AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, scheduled for payment on May 18, 2022. The record date for shareholders will be April 27, 2022. A conference call to discuss the first quarter results for 2022 is set for April 29, 2022, at 8:00 a.m. Central Time. Aptar is a leader in drug delivery and consumer product dispensing, employing approximately 13,000 individuals across 20 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
dividends
-
Rhea-AI Summary

AptarGroup, Inc. (NYSE: ATR) announces the sad passing of director Jesse Wu, who served on the Board since 2018 and was part of the Management Development & Compensation Committee. The company expresses deep condolences to his family, highlighting Wu's significant contributions, particularly in the Asian market. Aptar is a global leader in drug delivery and consumer product solutions, with 13,000 employees across 20 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
-
Rhea-AI Summary

AptarGroup, Inc. (NYSE: ATR) has announced a public offering of $400 million in aggregate principal amount of its 3.600% Senior Notes due 2032. The offering is expected to close on March 7, 2022, pending customary conditions. Proceeds will be used to repay outstanding amounts under its revolving credit facility and for general corporate purposes, including near-term debt repayment. The offering is managed by BofA Securities, HSBC, J.P. Morgan, and Wells Fargo Securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary

AptarGroup reported robust fourth quarter and annual results for 2021, showcasing a 9% increase in reported sales and a 10% rise in core sales. Annual sales reached a record $3.2 billion, with reported earnings per share climbing 12% to $3.61. The company made strategic acquisitions, including Voluntis and part of Weihai Hengyu Medical Products, enhancing its digital therapeutic and injectable drug delivery capabilities. Despite increased input costs impacting margins, Aptar's commitment to sustainability and cash dividends remains strong, concluding 2021 with $99 million in dividends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
none
-
Rhea-AI Summary

AptarGroup, Inc. (NYSE: ATR) has achieved a Platinum rating from EcoVadis, recognizing its sustainability efforts and placing it in the top 1% of 85,000 companies rated globally. This achievement reflects significant progress from Bronze to Gold and now to Platinum over the last eight years. The rating assesses performance across themes such as environment, labor and human rights, ethics, and sustainable procurement. Aptar’s commitment to sustainability aligns with partners like the Ellen MacArthur Foundation and the United Nations Global Compact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
Rhea-AI Summary

AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, payable on February 23, 2022, with a record date of February 3, 2022. The company will host a conference call on February 18, 2022, at 8:00 a.m. CT to discuss its fourth quarter and year-end results for 2021. Additionally, the 2022 Annual Meeting of Stockholders is scheduled for May 4, 2022, at 9:00 a.m. CT, with a record date for voting set for March 11, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
dividends

FAQ

What is the current stock price of Aptargroup (ATR)?

The current stock price of Aptargroup (ATR) is $120.1 as of June 22, 2026.

What is the market cap of Aptargroup (ATR)?

The market cap of Aptargroup (ATR) is approximately 7.7B.